New Pfizer, same problem
Pfizer’s chief executive has pledged to throw money at the pharma giant’s thin pipeline and shirk financial engineering, but only canny deal-making will keep investors on…
Cash-rich biotechs turn down the licensing deal volume
Last year saw a dip in licensing deals across biopharma, though up-front payments held up and in some areas jumped considerably.
Verastem plays the Kras card
For $3m Verastem adds to its pipeline another asset that a bigger company had given up on.
Corporate and regulatory developments over the Christmas period
On the corporate front Astellas continued to buy, while Qiagen decided that it was not, after all, up for sale.
Sarepta makes history with Roche deal
A bidding war has netted Sarepta the largest-ever licensing deal for a cell or gene therapy. Can Roche make it work?
Novo goes small with big Dicerna deal
Novo Nordisk takes its first step into RNA with a broad cardio-metabolic deal with Dicerna, the biggest sealed by the US biotech to date.
Ipsen doubles down on rare bone disease
Today’s deal with Blueprint gives Ipsen two shots at Fop, but makes its takeout of Clementia look even more expensive.
Reata looks to outsmart Abbvie again
Fresh from buying omaveloxolone and bardoxolone rights back from Abbvie, Reata sees the first part of the puzzle fall into place.
As the heat rises, Clovis turns to radionuclides
The beleaguered drug maker has licensed a preclinical FAP-directed radiopharmaceutical, a target that has made little progress.
